Surgical considerations for gastrointestinal stroma tumor;Gastrointestinale stromatumoren: Was der chirurg wissen muss

Chirurg

Volumn 77, Issue 1, 2006, Pages 33-40

  Hohenberger, P ^a,c   Wardelmann, E ^b  

^a UNIVERSITY HOSPITAL HEIDELBERG   (Germany)

^b UNIVERSITY OF BONN   (Germany)

^c UNIVERSITY OF HEIDELBERG   (Germany)

Author keywords

Adjuvant therapy; High risk group; Imatinib mesylate; R0 resection

Indexed keywords

CD34 ANTIGEN; STEM CELL FACTOR RECEPTOR; TUMOR MARKER;

APOPTOSIS; CANCER STAGING; GASTROINTESTINAL STROMAL TUMOR; GASTROINTESTINAL TRACT; GENE EXPRESSION REGULATION; GENETICS; HUMAN; LYMPH NODE METASTASIS; NUCLEOTIDE SEQUENCE; ONCOGENE RAS; PATHOLOGY; PHYSIOLOGY; PROGNOSIS; REVIEW;

ANTIGENS, CD34; APOPTOSIS; DNA MUTATIONAL ANALYSIS; GASTROINTESTINAL STROMAL TUMORS; GASTROINTESTINAL TRACT; GENE EXPRESSION REGULATION, NEOPLASTIC; GENES, RAS; HUMANS; LYMPHATIC METASTASIS; NEOPLASM STAGING; PROGNOSIS; PROTO-ONCOGENE PROTEINS C-KIT; TUMOR MARKERS, BIOLOGICAL;

EID: 31344462411     PISSN: 00094722     EISSN: None     Source Type: Journal    
DOI: 10.1007/s00104-005-1125-8     Document Type: Review

References (35)

1. Agaimy A, Wuensch PH (2005) Gastrointestinal stromal tumours in patients with other-type cancer: a mere coincidence or an etiological association? A study of 97 GIST cases. Z Gastroenterol 43(9):1025-1030
2. Andersson J, Sihto H, Meis-Kindblom JM, Joensuu H, Nupponen N, Kindblom LG (2005) NF1-associated gastrointestinal stromal tumors have unique clinical, phenotypic, and genotypic characteristics. Am J Surg Pathol 29(9):1170-1176
3. Blay JY, Bonvalot S, Casali P et al. (2005) Consensus meeting for the management of gastrointestinal stromal tumors. Report of the GIST Consensus Conference of 20-21 March 2004, under the auspices of ESMO. Ann Oncol 16(4)566-578
4. Breiner JA, Meis-Kindblom J, Kindblom LG et al. (2000) Loss of 14q and 22q in gastrointestinal stromal tumors (pacemaker cell tumors). Cancer Genet Cytogenet 120(2):111-116
5. Bumming P, Andersson J, Meis-Kindblom JM et al. (2003) Neoadjuvant, adjuvant and palliative treatment of gastrointestinal stromal tumours GIST. with imatinib: a centre-based study of 17 patients. Br J Cancer 89(3):460-464
6. Carney JA (1999) Gastric stromal sarcoma, pulmonary chondroma, and extra-adrenal paraganglioma (Carney Triad): natural history, adrenocortical component, and possible familial occurrence. Mayo Clin Proc 74(6)543-552
7. Debiec-Rychter M, Sciot R, Verweij J et al. (2006) C-KIT mutations should guide dose selection for imatinib in patients with advanced gastrointestinal stromal tumors. Results of mutation analysis in 377 patients entered into a randomized study (submitted)
8. DeMatteo RP, Lewis JJ, Leung D, Mudan SS, Woodruff JM, Brennan MF (2000) Two hundred gastrointestinal stromal tumors: recurrence patterns and prognostic factors for survival. Ann Surg 231(1)51-58
9. Demetri GD, von Mehren M, Blanke CD et al. (2002) Efficacy and safety of imatinib mesylate in advanced gastrointestinal stromal tumors. N Engl J Med 347(7):472-480
10. Gunawan B, Bergmann F, Hoer J et al. (2002) Biological and clinical significance of cytogenetic abnormalities in low-risk and high-risk gastrointestinal stromal tumors. Hum Pathol 33(3)316-321
11. Hartmann K, Wardelmann E, Ma Y et al. (2005) Novel germline mutation of KIT associated with familial gastrointestinal stromal tumors and mastocytosis. Gastroenterology 129(3):1042-1046
12. Hirota S, Isozaki K, Moriyama Y et al. (1998) Gain of function mutations of c-kit in human gastrointestinal sromal tumors. Science 279:577-580
13. Hirota S, Nishida T, Isozaki K et al. (2002) Familial gastrointestinal stromal tumors associated with dysphagia and novel type germline mutation of KIT gene. Gastroenterology 122(5):1493-1499
14. Hohenberger P, Bauer S, Schneider U et al. (2003) Tumor resection following imatinib pretreatment in GI stromal tumors. Proc Am Soc Clin Oncol 22:818
15. Hohenberger P, Reichardt P, Stroszczynski C, Schneider U, Hossfeld KD (2003) Gastrointestinale Stromatumoren (GIST - Tumorentität und Therapie mit Imatinib mesylat. Dtsch Ärztebl 100(23):1612-1618
16. Hohenberger P (2003) Neue Konzepte der Chirurgischen Therapie gastrointestinaler Stromatumoren. Viszeralchirurgie 38:379-386
17. Joensuu H, Roberts PJ, Sarlomo-Rikala M et al. (2001) Effect of the tyrosine kinase inhibitor STI571 in a patient with a metastatic gastrointestinal stromal tumor. N Engl J Med 344(14):1052-1056
18. Jost D, Stroszczynski C, Chmelik P et al. (2003) Morphologie gastrointestinaler Stromatumoren im fortgeschrittenen Stadium der Erkrankung: Ausgangsbefunde vor Chemotherapie mit Imatinib. Röfo Fortschr Geb Rontgenstr Neuen Bildgeb Verfahr 175(6):791-798
19. Kindblom LG, Remotti HE, Aldenborg F, Meis-Kindblom JM (1998) Gastrointestinal pacemaker cell tumor (GIPACT): gastrointestinal stromal tumors show phenotypic characteristics of the interstitial cells of Cajal. Am J Pathol 152(5):1259-1269
20. Mechtersheimer G, Lehnert T, Penzel R, Joos S, Egerer G, Otto HF (2003) Gastrointestinale Stromatumoren. Eine morphologisch und molekular eigenstandige Tumorentitat mit neuer therapeutischer Perspektive. Pathologe 24(3):182-191
21. Nilsson B, Bumming P, Meis-Kindblom JM et al. (2005) Gastrointestinal stromal tumors: the incidence, prevalence, clinical course, and prognostication in the preimatinib mesylate era - a population-based study in western Sweden. Cancer 15;103(4):821-829
22. Pierie JP, Choudry U, Muzikansky A, Yeap BY, Souba WW, Ott MJ (2001) The effect of surgery and grade on outcome of gastrointestinal stromal tumors. Arch Surg 136(4):383-389
23. Plaat BE, Hollema H, Molenaar WM et al. (2000) Soft tissue leiomyosarcomas and malignant gastrointestinal stromal tumors: differences in clinical outcome and expression of multidrug resistance proteins. J Clin Oncol 18:3211-3220
24. Reichardt P, Schneider U, Stroszczynski C, Pink D, Hohenberger P (2004) Histological response of gastrointestinal stromal tumor to treatment with tyrosine kinase inhibitor imatinib mesylate. J Clin Pathol
25. Ruka W, Rutkowski P, Nowecki Z, Nasierowska-Guttmejer A, Debiec-Rychter M (2004) Other malignant neoplasms in patients with gastrointestinal stromal tumors (GIST). Med Sci Monit 10(8):LE13-14
26. Singer S, Rubin BP, Lux ML et al. (2002) Prognostic Value of KIT Mutation Type, Mitotic Activity, and Histologic Subtype in Gastrointestinal Stromal Tumors. J Clin Oncol 20(18):3898-3905
27. Stroobants S, Goeminne J, Seegers MJ et al. (2003) 18FDG-Positron emission tomography for the early prediction of response in advanced soft tissue sarcoma treated with imatinib mesylate (Glivec®). Eur J Cancer 39(14):2012-2020
28. Stroszczynski C, Jost D, Reichardt P et al. (2005) Follow-up of gastro-intestinal stromal tumours (GIST, during treatment with imatinib mesylate by abdominal MRI. Eur Radiol 13
29. Tran T, Davila J, El-Serag HB (2005) The epidemiology of malignant gastrointestinal stromal tumors: an analysis of 1458 cases from 1992 to 2000. Am J Gastroenterol 100:162-168
30. Van Glabbeke M, Verweij J, Casali PG et al. (2005) Initial and late resistance to imatinib in advanced gastrointestinal stromal tumors are predicted by different prognostic factors: a European Organisation for Research and Treatment of Cancer-Italian Sarcoma Group-Australasian Gastrointestinal Trials Group study. J Clin Oncol 23:5795-5804
31. van Oosterom AT, Judson I, Verweij J et al. (2001) Safety and efficacy of imatinib (STI571. in metastatic gastrointestinal stromal tumours: a phase I study. Lancet 358(9291):1421-1423
32. Verweij J, Casali PG, Zalcberg J et al. (2004) Progression-free survival in gastrointestinal stromal tumours with high-dose imatinib: randomised trial. Lancet 364(9440):1127-1134
33. Wardelmann E, Neidt I, Bierhoff E et al. (2002) c-kit mutations in gastrointestinal stromal tumors occur preferentially in the spindle rather than in the epithelioid cell variant. Mod Pathol 15(2):125-136
34. Wardelmann E, Thomas N, Merkelbach-Bruse S et al. (2005) Acquired resistance to imatinib in gastrointestinal stromal tumours caused by multiple KIT mutations. Lancet Oncol 6(4):249-251
35. Wong NACS, Young R, Malcomson et al. (2003) Prognostic indicators for gastrointestinal stromal tumors: a clinicopathological and imunohistochemical study of 108 resected cases of the stomach. Histopathology 43:118-126